Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,171 shares of the medical research company’s stock after purchasing an additional 509 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Edwards Lifesciences were worth $827,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Peoples Bank KS bought a new position in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on EW shares. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Citigroup raised their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $79.40.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $70.29 on Thursday. The company’s fifty day moving average is $71.82 and its two-hundred day moving average is $71.62. The company has a market cap of $41.46 billion, a P/E ratio of 10.14, a price-to-earnings-growth ratio of 3.61 and a beta of 1.11. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. Equities analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,500 shares of company stock valued at $2,160,800. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.